Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleBEHAVIORAL PHARMACOLOGY

Human Urocortin II, a Selective Agonist for the Type 2 Corticotropin-Releasing Factor Receptor, Decreases Feeding and Drinking in the Rat

Koki Inoue, Glenn R. Valdez, Teresa M. Reyes, Lindsay E. Reinhardt, Antoine Tabarin, Jean Rivier, Wylie W. Vale, Paul E. Sawchenko, George F. Koob and Eric P. Zorrilla
Journal of Pharmacology and Experimental Therapeutics April 2003, 305 (1) 385-393; DOI: https://doi.org/10.1124/jpet.102.047712
Koki Inoue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenn R. Valdez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa M. Reyes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsay E. Reinhardt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Tabarin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Rivier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wylie W. Vale
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul E. Sawchenko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George F. Koob
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric P. Zorrilla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Corticotropin-releasing factor (CRF) has been hypothesized to modulate consummatory behavior through the Type 2 CRF (CRF2) receptor. However, behavioral functions subserved by the CRF2 receptor remain poorly understood. Recently, human urocortin II (hUcn II), a selective CRF2 receptor agonist, was identified. To study the effects of this neuropeptide on ingestive behavior, we examined the effects of centrally infused hUcn II (i.c.v. 0, 0.01, 0.1, 1.0, 10.0 μg) on the microstructure of nose-poke responding for food and water in nondeprived, male rats. Malaise-inducing properties of the peptide were monitored using conditioned taste aversion (CTA) testing. To identify potential sites of action, central induction of Fos protein expression was examined. hUcn II dose dependently reduced the quantity and duration of responding for food and water at doses lower (0.01–1.0 μg) than that forming a CTA (10 μg). Effects were most evident during hours 4 to 6 of the dark cycle. Meal pattern analysis showed that hUcn II potently (0.1 μg) increased the satiating value of food. Rats ate and drank smaller and shorter meals without changing meal frequency. Rats also ate more slowly. hUcn II induced Fos in regions involved in visceral sensory processing and autonomic/neuroendocrine regulation and resembling those activated by appetite suppressants. hUcn II is a promising neuropeptide for investigating the role of the CRF2 receptor in ingestive behavior.

Footnotes

  • This work was supported by DK26741 from the National Institute of Diabetes and Digestive and Kidney Diseases. G.R.V. was supported by AA05563, an Individual National Research Service Award from the National Institute of Alcohol Abuse and Alcoholism. E.P.Z. was supported by a Minority Research Supplement to DK26741.

  • DOI: 10.1124/jpet.102.047712

  • Abbreviations:
    CRF
    corticotropin-releasing factor
    hUcn II
    human urocortin II
    d-Phe CRF12–41
    [d-Phe12, Nle21,38 Cα MeLeu37] rat/human CRF12–41
    CTA
    conditioned taste aversion
    Ucn
    urocortin
    mUcn II
    murine urocortin II
    ANOVA
    analysis of variance
    MED
    minimum effective dose
    CeA
    central nucleus of the amygdala
    NTS
    nucleus of the solitary tract
    SKF 38393
    2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
    • Received December 4, 2002.
    • Accepted December 10, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 305 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 305, Issue 1
1 Apr 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Human Urocortin II, a Selective Agonist for the Type 2 Corticotropin-Releasing Factor Receptor, Decreases Feeding and Drinking in the Rat
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleBEHAVIORAL PHARMACOLOGY

Human Urocortin II, a Selective Agonist for the Type 2 Corticotropin-Releasing Factor Receptor, Decreases Feeding and Drinking in the Rat

Koki Inoue, Glenn R. Valdez, Teresa M. Reyes, Lindsay E. Reinhardt, Antoine Tabarin, Jean Rivier, Wylie W. Vale, Paul E. Sawchenko, George F. Koob and Eric P. Zorrilla
Journal of Pharmacology and Experimental Therapeutics April 1, 2003, 305 (1) 385-393; DOI: https://doi.org/10.1124/jpet.102.047712

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleBEHAVIORAL PHARMACOLOGY

Human Urocortin II, a Selective Agonist for the Type 2 Corticotropin-Releasing Factor Receptor, Decreases Feeding and Drinking in the Rat

Koki Inoue, Glenn R. Valdez, Teresa M. Reyes, Lindsay E. Reinhardt, Antoine Tabarin, Jean Rivier, Wylie W. Vale, Paul E. Sawchenko, George F. Koob and Eric P. Zorrilla
Journal of Pharmacology and Experimental Therapeutics April 1, 2003, 305 (1) 385-393; DOI: https://doi.org/10.1124/jpet.102.047712
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cromakalim prodrugs are analgesics in chronic pain models
  • Role of Residues S426 and S430 in Cannabinoid Tolerance
  • Running Title: Stimulus effects of nicotine aerosol
Show more Behavioral Pharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics